Stock Details
LLY is Eli Lilly and Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 298.47$. Average daily volumn in 3 months 3.1M. Market cap 310.96B

Stock symbol : LLY. Exchange : NYSE. Currency : USD
Lastest price : 327.27$. Total volume : 3.18M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Eli Lilly and Company (LLY)
Last Price

Previous Close325.62
Day Range322.00-330.85
Bid322.11 x 1.3k
Ask326.77 x 1k
Average Volume3.1M
Market Cap310.96B
52 Week Range220.20-330.85
Trailing P/E48.64
Foward P/E36.40
Dividend (Yield %)1.32%
Ex-Dividend Date2022-05-13

Financial Details

According to Eli Lilly and Company's financial reports the company's revenue in 2021 were 28.32B an increase( +16.67%) over the years 2020 revenue that were of 24.54B. In 2021 the company's total earnings were 5.58B while total earnings in 2020 were 6.19B(-16.67%).

Loading ...



Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramz... a for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Market Cap:
Total Assets:
Total Cash:

News about "Eli Lilly and Company"


Lilly Declares Third-Quarter 2022 Dividend

Source from : Yahoo - 16 hours ago

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock.See details»


Eli Lilly and Company (NYSE:LLY) Shares Purchased by AdvisorNet Financial Inc

Source from : Defense World - 1 days ago

AdvisorNet Financial Inc raised its position in shares of Eli Lilly and Company (NYSE:LLY โ€“ Get Rating) by 29.3% in the first quarter, according to its most recent 13F filing with the Securities & ...See details»


Eli Lilly and Company (NYSE:LLY) Shares Acquired by YHB Investment Advisors Inc.

Source from : ETF Daily News - 1 days ago

YHB Investment Advisors Inc. grew its stake in Eli Lilly and Company (NYSE:LLY โ€“ Get Rating) by 5.7% in the 1st quarter, according to the company in its most recent filing with the Securities & ...See details»


YHB Investment Advisors Inc. Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Source from : Defense World - 1 days ago

YHB Investment Advisors Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY โ€“ Get Rating) by 5.7% during the first quarter, Holdings reports. The firm owned 1,933 shares of the ...See details»

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Source from : YAHOO!Finance - 12 hours ago

In the latest trading session, Eli Lilly (LLY) closed at $327.27, marking a +0.51% move from the previous day.See details»

Eli Lilly and Company (NYSE: LLY): Making Its Way Up The Stock Market

Source from : stocksregister - 3 days ago

Eli Lilly and Company (NYSE:LLY) shares, rose in value on Friday, June 24, with the stock price up by 3.92% to the previous dayโ€™s close as strong demand from buyers drove the stock to $324.97.See details»


Eli Lilly and Company (NYSE:LLY) Shares Acquired by NuWave Investment Management LLC

Source from : ETF Daily News - 3 days ago

Eli Lilly and (NYSE:LLY โ€“ Get Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate ...See details»

Eli Lilly and Company (LLY) intends to increase sales of immunological illness medications

Source from : stocksregister - 5 days ago

Despite certain hiccups, advanced treatment maker Eli Lilly and Company (NYSE: LLY) intends to increase sales of its immunological illness medications. The FDA expressed concerns about the safety of ...See details»


Eli Lilly: Unstoppable Share Price Progress Can't Last Forever

Source from : Seeking Alpha - 3 days ago

Lilly's share price is +39% over a 12m period, and +293% across the past 5 years. Read more about LLY stock here.See details»


Novartis Follows Eli Lilly With $1.4 Billion Gene-Editing Pact

Source from : - 5 days ago

Gene editing is the process of changing a person's genome to treat or cure a disease. Many gene editing tools rely on enzymes called nucleases. These enzymes cut DNA to facilitate gene editing. For ...See details»


Why Eli Lilly's Immunology Prospects Look Promising

Source from : Nasdaq - 7 days ago

Top pharmaceutical company Eli Lilly's (NYSE: LLY) diabetes division achieved a key milestone with the approval of Mounjaro in May for type 2 diabetes. But not to be outdone, the company's immunology ...See details»


โ€˜Families will prosper.โ€™ Eli Lilly breaks ground in Concord on $1 billion medicine plant

Source from : Raleigh News & Observer - 13 days ago

The billion-dollar investment is expected to produce hundreds of new jobs. Eli Lilly could start producing medicine in Cabarrus County by 2024.See details»


Baron Funds: โ€œWe Retain Conviction in Eli Lilly (LLY)โ€

Source from : Insider Monkey - 12 days ago

Baron Funds, an asset management firm, published its โ€œBaron Health Care Fundโ€ first quarter 2022 investor letter โ€“ a copy of which can be downloaded here.See details»


Pharmaceutical giant Eli Lilly targets production start as it breaks ground on $1B campus in Concord (PHOTOS)

Source from : The Business Journals - 12 days ago

State and local leaders are hopeful that Eli Lilly's $1 billion investment in Concord can help pave the way for the Charlotte region to get in the game in life sciences manufacturing in a significant ...See details»